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BIOCHEMISTRY AND NATURAL HISTORY OF 
G6PD DEFICIENCY
G6PD is an enzyme in the pentose phosphate pathway,
a metabolic pathway that supplies reducing energy to 
cells, in particular erythrocytes, by maintaining the 
level of nicotinamide adenine dinucleotide phosphate 
(NADPH). NADPH in turn maintains the level of 
glutathione that helps protect erythrocytes against 
oxidative damage.  In states of oxidative stress, 
glutathione is rapidly consumed and the build up of 
oxidants can cause the red cell to lyse. Hence, G6PD 
deficiency most commonly manifests as either 
prolonged neonatal jaundice or acute hemolytic anemia.  
Patients of G6PD deficiency are almost exclusively 
male, due to the X-linked pattern of inheritance, but 
female carriers can be clinically affected due to 
lyonization.  Lyonization is the random inactivation of 
an X-chromosome in certain cells, which creates a 
population of G6PD deficient erythrocytes coexisting 
with normal cells. 
The peak incidence of neonatal jaundice occurs during 
the second or third day of life.  The severity of the
jaundice ranges from subclinical to levels compatible 
with kernicterus, a condition in infants 
characterized by damage to brain centers due to high 
levels of bilirubin.  Acute hemolytic anemia usually 
begins within hours of an oxidative stress and ends 
when G6PD deficient erythrocytes have hemolyzed; 
therefore, the severity of the anemia associated with 
these acute hemolytic episodes is proportionate to the 
deficiency of G6PD and oxidative stress.  Viral and 
bacterial infections are the most common triggers, but 
many drugs and toxins can also precipitate hemolysis 
(3).  The disorder, favism, in a G6PD deficient patient 
results from hemolysis secondary to the ingestion of 
fava beans, which contain  beta-glycosides and
naturally occurring oxidants.  One such peroxidative
component of fava beans is divicine, which reduces
catalase activity in G6PD-deficient erythrocytes (14).  
Interestingly, G6PD deficiency also increases the risk 
for certain unrelated diseases.   For example, it has been 
shown that there is an increased clinical incidence of 
G6PD deficiency in female patients with multi-lineage 
clonal marrow disorders (15).  
Likewise, G6PD deficiency has been implicated in the 
pathogenesis of a number of common diseases.  It has 
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Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency, a hereditary predisposition to hemolysis, is 
an X-linked disorder of antioxidant homeostasis that is 
caused by mutations in the G6PD gene. An estimated 
four hundred million people worldwide are affected. 
Hence, G6PD deficiency is the most common 
enzymopathy in the world (3). In areas where malaria 
is endemic, G6PD deficiency has a prevalence of 5% to 
25%. Non-endemic areas have less than 5% of their 
population afflicted with the disease. Several 
epidemiology studies have identified pockets in Asia 
and the Middle East with prevalence of the disease as 
high as 62% (Kurdish Jews) (1) and 31% (Northern 
Vietnam) (2). Within certain population subgroups of 
the North America, especially blacks, and also among 
descendents of immigrants from East Asia, Southeast 
Asia, Greece, Italy and Sephardic Jews, the incidence 
of G6PD deficiency may be sufficiently high to merit 
concern (4). 
In light of the high prevalence of this disease in 
many populations around the world, newborn 
screening for G6PD deficiency has been implemented 
and incorporated into the screening program in several 
non-western countries, such as in the Middle East, 
Eastern Europe and Southeast Asia (5).  An analysis of 
the cost-effectiveness of G6PD deficiency population 
screening in Canada is necessary, considering the 
significant influx of immigrants from at-risk 
populations in Canada over the last 50 years.  On 
average, around a hundred and fifty thousand new 
migrants uproot themselves from regions  around  he 
globe to establish themselves in Canada each year. This 
massive change in demographics has been 
exceptionally pronounced in the past decade. 
Immigration numbers have surged to over two hundred 
thousand per year; the majority (~70%) of these new 
Canadians come from Asia, the pacific,  Africa and the 
Middle East (6).
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decrease in the generation of nitric oxide (NO), 
which are the pathologic characteristics found in G6P 
deficiency, have been connected to the development of 
hypertension, diabetes mellitus and atherosclerosis. 
NADPH, which is generated by G6PD, is a co-factor in 
the synthesis of nitric oxide.  Hence, G6PD deficiency 
could result in lower NO production.  In addition, G6PD 
deficiency could lead to hyperglycemia, making more 
glucose available for the non-enzymatic production of 
advanced glycosylation end products.  It has been 
suggested that these end-products ultimately increase 
superoxide anions and quench nitric oxide (16). 
Cardiac dysfunction might also be aggravated by a 
deficiency in G6PD.  As G6PD is a critical antioxidant 
enzyme, essential for maintenance of cytosolic redox 
status in cardiomyocytes, deficiencies may contribute to 
cardiac dysfunction through increased susceptibility to 
free radical injury and impairment of intracellular 
calcium transport (17).
G6PD deficiency might also exaggerate morbidity in 
some infections and increase the risk of Toxoplasmosis
infection by 2.5 fold. G6PD deficiency affects our
immune response to infection in two contrasting ways.
The first mechanism that has been suggested is an 
exaggeration of the inflammatory response.  It has been 
observed that severely injured G6PD deficient patients 
tend to have an augmented inflammatory response 
compared to non-deficient trauma patients.  A 
reduction in the capacity to produce IL-10, a signaling 
molecule involved in immunosuppression and 
regulation of T helper cell responses, may be an 
intrinsic characteristic of G6PD-deficient monocytes; 
this attenuated production might be a contributing 
mechanism to the difference in the level of 
inflammation observed (18).   The second mechanism is
a decrease in the normal phagocytic response (19). 
Indeed, the production of H 2O2 and superoxide has 
been found to be also significantly impaired in G6PD-
deficient granulocytes (20). 
G6PD-D-HEMOLYSIS-INDUCING DRUGS
As previously established, understanding of the 
adverse effects of drugs in G6PD deficiency is 
quintessential for the post-natal counseling of this 
enzymopathy.  A number of drugs have been reported to 
have a potential hemolytic effect on G6PD-deficient 
individuals. These include primaquine,
chloramphenicol and sulfanilamide, which in one study, 
caused significant concentration-dependent reductions 
of glutathione levels in G6PD-deficient red cells when 
compared to normal red cells (21).   Several other drugs 
have been found to be associated with G6PD 
deficiency-related hemolytic events but the precise 
causative link has not been fully investigated.  Some 
examples in case reports are glyburide (22), methylene 
blue (23, 24), nitrofurantoin and aspirin.  G6PD
deficient individuals might also be at greater risk of 
being exposed to hemolytic inducing environmental or 
household chemicals in addition to the prescribed drugs 
mentioned above. Such triggers include naphthalene 
(25) and henna (26, 27, 28).
MANAGEMENT OF G6PD DEFICIENCY
G6PD deficiency should be suspected in patients of 
African, Mediterranean, or Asian ancestry who present 
with either an acute hemolytic episode or neonatal 
jaundice.  Unfortunately, according to Kaplan and 
Hammerman (4), many pediatricians and 
neonatologists practicing in the United States or Canada 
erroneously regard G6PD deficiency as a condition 
confined to the Middle East or Orient and with little 
application to the patients under their care.  The 
importance of eliciting an adequate ethnic background 
history from both parents cannot be underestimated. 
Compounding this ignorance, is the false impression 
amongst many physicians that only G6PD-deficient 
premature infants are at increased risk for spontaneous 
hemolysis or neonatal hyperbilirubinemia while full 
term G6PD-deficient neonates of this population 
subgroup go unaffected (4).  
The key to management of G6PD deficiency is 
prevention of hemolysis by prompt treatment of 
infections and avoidance of drug and household 
triggers, which are discussed in a later section of this 
paper.  Patients presenting with severe anemia and 
hemolysis may require resuscitation and erythrocyte 
transfusion, while babies with neonatal jaundice tend to 
respond well to standard therapies like hydration, light 
therapy and exchange transfusion (3).  Thus, if a
neonate is found to be G6PD deficient, counselling for 
the parents and an establishment of breastfeeding 
practices might be excellent prophylactic measures in
preventing hemolytic crises later in life.  Undoubtedly,
a good knowledge of chemotherapeutic drugs,
household agents and other environmental triggers of
hemolytic anemia in G6PD deficiency are vital for all
physicians to not only reduce the incidence of
iatrogenic-induced hemolytic events but also augment
awareness amongst at-risk individuals.
NEONATAL SCREENING FOR G6PD
DEFICIENCY
The most eminent public health efforts in genetics
are government-driven programs that carry out neonatal 
population screening to identify infants with genetic 
disorders for which early treatment can prevent or at 
least ameliorate the consequences. Genetic 
screening can identify persons with genotypes 
associated with disease, carrier states or predisposition 
to disease by examining all members of a designated 
population, regardless of family history.  To date, this 
public health activity for G6PD deficiency has not been 
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Table 1. Adapted from reference 29
CRITERIA FOR NEWBORN SCREENING
1 Treatment has to be available
2 Early institution of treatment before symptoms manifests has
been shown to reduce the severity of the illness
3 Routine observation and physical examination will not reveal the
disorder and so a test is required
4 A rapid and economical laboratory test is available that is highly
sensitive and specific
5 The condition is frequent and serious enough to justify the
expense of screening (cost-effectiveness)
6 The social infrastructure is in place to inform the newborn's
parents and physicians of the results of the screening test, confirm
the test results, and institute appropriate treatment and counselinginitiated in Canada.  In order to determine whether the 
G6PD deficiency screening should be implemented as 
the standard procedure in Canada, one should first 
determine its suitability and cost-effectiveness by 
consulting the criteria in Table 1 for guidance (29).
DOES NEONATAL SCREENING FOR G6PD 
DEFICIENCY MEET THE CRITERIA?
Screening for G6PD deficiency does abide by the 
above criteria to some extent.  Though a cure does not 
exist for this condition, recognizing that kernicterus is a 
serious contributor to newborn mortality and morbidity 
in G6PD deficient babies should be enough of an 
impetus to start preventive measures.  The onset of 
kernicterus could be curbed by prophylactic avoidance 
of triggers and rapid instigation of treatment for 
infections.
Singapore has embraced this concept and 
established a mass newborn screening program for 
G6PD deficiency in 1965. G6PD deficient newborns are 
identified at birth by measuring the G6PD activity in 
cord blood. They are then physically protected from 
triggers by keeping them in the hospital for up to the 
first two weeks of life.  Their parents are counseled on
the drugs and household triggers of hemolytic crises.
With these preventative measures, the incidence of 
kernicterus has dropped dramatically and in the last 20 
years, there has been only one reported case of 
kernicterus in newborns with G6PD deficiency in 
Singapore (5).
A later study done in Singapore revealed that 55% of 
G6PD-deficient newborns did not require phototherapy 
at all (30).  This implies that without newborn screening 
to identify asymptomatic G6PD deficient newborns, 
these infants run a greater risk of unexpected hemolytic 
anemia if they unknowingly expose themselves to 
hemolytic triggers later in life.  This goes to show that 
early institution of treatment does reduce or eliminate 
morbidity of the disease, which satisfies the second 
criteria for newborn screening.  Furthermore, clinically 
asymptomatic G6PD deficient neonates, who represent 
a large proportion of all afflicted neonates (30), cannot 
be picked up by routine physical examinations.  This 
means that a laboratory test is warranted to distinguish 
normal from diseased and, for this reason, the third 
criterion for newborn screening is fulfilled.
To meet the fourth criteria for neonatal screening, an 
economical laboratory test must be available.  A rapid 
and inexpensive test for G6PD activity in erythrocytes, 
namely, the Beutler fluorescent spot test is in existence. 
The test works by visually identifying NADPH 
produced by G6PD under ultraviolet light.  
Situated in a region endemic to malaria, the fifth 
criteria for newborn screening of G6PD deficiency was 
easily met in Singapore.  Singapore has identified three 
clinical syndromes associated with G6PD deficiency, 
namely, severe hemolysis in neonates with kernicterus, 
and hemoglobinuria.  Among the Chinese in Singapore, 
three common molecular variants, Canton, Kaiping and 
Mediterranean, have been identified to occur in higher 
frequencies. In Malays, 6 different deficient variants are 
known to occur with significant frequencies in 
Singapore (12). A later study on the incidence of this
deficiency led to the observation of racial frequency
variation, that is, G6PD deficiencies in 3.94% of
Chinese infants, 2.95% of Malays and 0.66% of Indians
(3).
Nonetheless, despite G6PD deficiency being one of 
the most common inherited metabolic disorders, the 
magnitude of the problem in Canada is unknown and 
studies in North America have not determined the 
incidence of severe hyperbilirubinemia in G6PD-
deficient neonates in any subgroups with a high 
potential for G6PD deficiency in North America.  A 
large epidemiological study of G6PD-deficiency-
associated neonatal hyperbilirubinemia in high-risk 
minority population subgroups would be necessary to 
elucidate the true dimensions of the problem (4). 
Consequently, the fifth criterion for newborn screening 
of G6PD deficiency in Canada or the United States is
not met until sufficient research is carried 
out in this part of the world.  
CONCLUSION
Rapid changes in the ethnic make-up of the Canadian 
population in recent times have resulted in more 
diversity in Canada.  This expanding diversity on one 
hand enriches the cultural and social front but, on the 
other hand, puts additional demands on the healthcare 
system.  Physicians need to be constantly vigilant in 
assessing genetic diseases and the ethnic-specific health 
problems of their patients.  
Moreover, it is also reasonable to infer that G6PD 
deficiency is on the rise in Canada.  Along side, an 
increase incidence of the disease complications, such as 
kernicterus and hemolytic anemia, would probably 
ensue.  Therefore, making adjustments to Canada's 
health management plans, to effectively treat this 
genetic disorder, is essential.  These changes could 
include the implementation of newborn screening of at-
risk population to identify deficient individuals, 
extensions of hospital stays for afflicted newborns, the 
rapid treatment of infections, and the initiation of 
counseling for G6PD-deficiency families.  Counseling 
G6PD families should be aimed at increasing awareness
of hemolytic triggers.  In addition, the above 
measures have to be executed in conjunction with a 
better understanding of chemical exposure-related 
hemolytic events in G6PD deficiency.  For this reason, 
it is important to initiate and accelerate research aimed 
at uncovering other agents which could cause hemolysis 
in patients with metabolic and blood pathologies.
In order to satisfy the criteria for newborn screening, 
investigations must to be devoted to measuring the 
frequencies of G6PD mutations in the Canadian 
populations and collecting data on the incidence of 
kernicterus and hemolytic anemia in G6PD deficient 
individuals.  Thereafter, a more accurate cost-benefit 
analysis of a neonatal screening program for G6PD 
deficiency can be performed. 
REFERENCES
1. Steensma DP, Hoyer JD, Fairbanks VF. Hereditary Red Blood
Cell Disorders in Middle Eastern Patients. Tutorial: Mayo Clinic
Proceedings. 2001 Mar; 76(3):285-93. 
2. Verle P, Nhan DH, Tinh TT, Uyen TT, Thuong ND, Kongs A,
Stuyft P, Coosemans M. Glucose-6-phosphate Dehydrogenase
Deficiency in Northern Vietnam. Tropical Medicine &
International Health. 2000 Mar; 5(3):203-6.
3. Boerkoel S, Yip YY: Mass Newborn Screening for Glucose-6-
Phosphate Dehydrogenase Deficiency in Singapore. Southeast
Asian Journal of Tropical Medicine & Public Health.  30 Suppl
Glucose-6-Phosphate Dehydrogenase Deficiency 33 Vol. 10  No. 21999; 2:70-1.
4. Kaplan M, Hammerman C. Glucose-6-phosphate
Dehydrogenase -deficient Neonates. A Potential Cause for
Concern in North America. Pedriatrics. 2000 Dec; 16(6):1478-
9.
5. Joseph R, Ho LY, Gomez JM, Rajdurai VS, Sivasankaran S, Yip
YY. Mass Newborn Screening for Glucose-6-phosphate
Dehydrogenase Deficiency in Singapore. Southeast Asian
Journal of Tropical Medicine & Public Health. 30 Suppl 1999;
2:70-1. 
6. Facts and Figures 2002: Immigration Overview. In
http://www.cic.gc.ca/english/pub/facts2002/index.html.
Accessed on 20 November 2004
7. Migot-Nabias F,  Mombo LE,  Luty AJ,  Dubois B,  Nabias R,
Bisseye C,  Millet P,  Lu CY,  Deloron P. Human Genetic Factors
Related to Susceptibility to Mild Malaria in Gabon. Genes &
Immunity. 2000 Oct; 7:435-41.
8. Ahmed SG, Ibrahim UA: Clinical Significance of Glucose-6-
Phosphate Dehydrogenase Deficiency in Nigerian Patients with
Sickle Cell Disease. Nigerian Postgraduate Medical Journal.
2002 Dec; 9(4):181-5.
9. Aster JC. Red Blood Cell and Bleeding Disorders.  In Kumar V,
Abul K, Fausto N. Robbins and Contran Pathologic Basis of
Disease, 7th ed, Philadelphia: Elsevier Saunders; 2005: 619-
659.
10. Lang KS,  Roll B,  Myssina S,  Schittenhelm M,  Scheel-Walter
HG,  Kanz L,  Fritz J,  Lang F,  Huber SM,  Wieder T. Enhanced
Erythrocyte Apoptosis in Sickle Cell Anemia, Thalassemia and
Glucose-6-phosphate Dehydrogenase Deficiency. Cellular
Physiology & Biochemistry 2002; 12(5-6):365-72.
11. Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate
Dehydrogenase Deficiency.  Balliers Best Prac Res Clin
Hematol 2000; 13:2.
12. Quak SH,  Saha N,  Tay JS. Glucose-6-phosphate
Dehydrogenase Deficiency in Singapore. Annals of the
Academy of Medicine, Singapore.  1996 Jan; 25(1):45-8.
13. Huang CS, Hung KL, Huang MJ, Li YC, Liu TH, Tang TK.
Neonatal Jaundice and Molecular Mutations in Glucose-6-
phosphate Dehydrogenase Deficient Newborn Infants.
American Journal of Hematology 1996 Jan; 51(1):19-25.
14. Gaetani GF,  Rolfo M,  Arena S,  Mangerini R,  Meloni GF,
Ferraris AM.  Active Involvement of Catalase during Hemolytic
Crises of Favism. Blood Aug 1 1996; 88(3):1084-8.
15. Au WY,  Ma SK,  Lie AK,  Liang R,  Cheng T,  Kwong YL.
Glucose-6-phosphate Dehydrogenase Deficiency and
Hematopoietic Stem Cell Transplantation. Bone Marrow
Transplantation 2002 Mar; 29(5):399-402.
16. Gaskin RS,  Estwick D,  Peddi R.  G6PD Deficiency: Its Role in
the High Prevalence of Hypertension and Diabetes Mellitus.
Ethnicity & Disease 2001 Fall; 11(4):749-54.
17. Jain M,  Brenner DA,  Cui L,  Lim CC,  Wang B,  Pimentel DR,
Koh S,  Sawyer DB, Leopold JA, Handy DE,  Loscalzo J,
Apstein CS,  Liao R. Glucose-6-phosphate Dehydrogenase
Modulates Cytosolic Redox Status and Contractile Phenotype in
Adult Cardiomyocytes. Circulation Research 2003 Jul 25;
93(2):9-16.
18. Liese AM,  Siddiqi MQ,  Siegel JH,  Deitch EA,  Spolarics Z.
Attenuated Monocyte IL-10 Production in Glucose-6-phosphate
Dehydrogenase-deficient Trauma Patients.  Shock 2002 Jul;
18(1):18-23.
19. Tabbara KF,  Sharara NA,  Al-Momen AK.  Toxoplasmosis in a
Group of Glucose-6-phosphate Dehydrogenase Deficient
patients. Saudi Medical Journal 2001 Apr; 22(4):330-2.
20. Tsai KJ, Hung IJ,  Chow CK,  Stern A,  Chao SS,  Chiu DT.
Impaired Production of Nitric Oxide, Superoxide, and Hydrogen
Peroxide in Glucose 6-phosphate-dehydrogenase-deficient
Granulocytes. FEBS Letters 1998 Oct 9; 436(3):411-4.
21. Ali NA,  al-Naama LM,  Khalid LO. Haemolytic Potential of
Three Chemotherapeutic Agents and Aspirin in Glucose-6-
phosphate Dehydrogenase Deficiency. Eastern Mediterranean
Health Journal 1999 May; 5(3):457-64.
22. Meloni G,  Meloni T: Glyburide-induced Acute Hemolysis in a
G6PD-deficient Patient with NIDDM. British Journal of
Haematology 1996 Jan; 92(1):159-60.
23. Liao YP,  Hung DZ,  Yang DY. Hemolytic Anemia after
Methylene Blue Therapy for Aniline-induced
Methemoglobinemia. Veterinary & Human Toxicology 2002
Feb; 44(1):19-21.
24. Gauthier TW:  Methylene Blue-induced Hyperbilirubinemia in
Neonatal Glucose-6-phosphate Dehydrogenase (G6PD)
Deficiency. Journal of Maternal-Fetal Medicine 2000 Jul-Aug;
9(4):252-4.
25. Santucci K,  Shah B. Association of Naphthalene with Acute
Hemolytic Anemia. Academic Emergency Medicine 2000 Jan;
7(1):42-7.
26. Kok AN,  Ertekin MV,  Ertekin V,  Avci B. Henna (Lawsonia
inermis Linn.) Induced Hemolytic Anemia in Siblings.
International Journal of Clinical Practice 2004 May; 58(5):530-
2.
27. Kandil HH,  al-Ghanem MM,  Sarwat MA,  al-Thallab FS.
Henna (Lawsonia inermis Linn.) Inducing Hemolysis among
G6PD-deficient Newborns. A New Clinical Observation. Annals
of Tropical Paediatrics 1996 Dec; 16(4):287-91.
28. Zinkham WH,  Oski FA: Henna: a Potential Cause of Oxidative
Hemolysis and Neonatal Hyperbilirubinemia. Pediatrics.  1996
May; 97(5):707-9.
29. Nussbaum RL, McInnes RR, Willard HF Thompson and
Thompson Genetics in Medicine, 6th ed, Philadelphia: WB
Saunders Company;391-398 
30. Lim HH, Daniel LM, Lee J, Tan MC. Predicting Significant
Hyperbilirubinaemia and Early Discharge for Glucose-6-
phosphate Dehydrogenase Deficient Newborns. Annals of the
Academy of Medicine, Singapore 2003 Mar; 32(2):257-61.
34 2007 McGill Journal of Medicine
Aaron Leong  (M.D. C.M. 2007) is a fourth-year medical
student at McGill University.  He received his B.Sc. in
Physiology from the National University of Singapore in
2002.  He hopes to train in internal medicine or pediatrics and
specialize in critical care.  His interests include both
qualitative and quantitative research in sociobiology,
epidemiology, public health and medical education.  He has
published in Medical informatics and the Internet in medicine
on multi-channel video methods used to assess the
effectiveness of clinical consultations.